And the habit that they focused on in particular was this issue about adding salts to food
"Often, it's something that may have a marginal pathway towards approval, or a really long time toward approval." The patient had been treated with tirzepatide Lilly's own dual-agonist obesity drug, sold as Zepbound, which the FDA approved in 2023 for approximately a year but achieved only moderate weight loss, according to sources familiar with the matter
The medicine is evolving quickly, having already expanded to include oral treatments with the first-ever FDA approval for a GLP-1 pill for weight loss for Wegovy at the end of 2025
It can help improve insulin sensitivity, lower blood pressure, reduce the risk of cardiovascular diseases, and enhance overall well-being
As always, it's essential to consult your primary healthcare practitioner before starting or changing a supplement routine
Fill nutrient gaps on GLP-1s GLP-1s reduce appetite, which can make it tough to get all the nutrients your body needs